This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Investigating the Preclinical Development of [161Tb]Tb-NYM032 for PSMA-targeting Radioligand Therapy

Investigating the Preclinical Development of [161Tb]Tb-NYM032 for PSMA-targeting Radioligand Therapy

12:00 pm - Thursday 23rd July 2026

Profiling biomarkers to reveal individual treatment responses, helping identify which patients are most likely to benefit from therapy
Tailoring dosimetry for each patient to optimize efficacy and safety by adjusting doses based on personalized radiation exposure
Speeding early development through data-driven personalization, using patient-specific information to guide decision-making and trial design

Speakers:

Waisi Eng

Waisi Eng

Chief Technology Officer

Norroy Bioscience CO., LTD